top of page
Nelson Advisors > European Healthcare Technology Investment Banking


The Shift to Proactive Medicine: An Industrial and Clinical Analysis of Neko Health’s $700 Million Series C Round and Global ScaleUp
The global venture capital landscape in 2025 and 2026 has witnessed a pronounced polarization. While macroeconomic pressures have forced a sharp reset in capital intensity for early-stage health technology startups, later-stage funding has increasingly concentrated in a select group of heavily capitalised, vertically integrated platforms. This trend culminated in the announcement that Stockholm-based preventative diagnostics firm Neko Health raised $700 million in a Series C
Nelson Advisors
Jul 15


Clinical and Economic Evaluation of Autonomous Artificial Intelligence in Musculoskeletal Therapeutics: Flok Health's Series A and the Shifting Competitive Landscape
Flok Health’s oversubscribed $12.5M Series A round highlights a broader maturation of autonomous clinical AI in regulated medical environments. By securing CQC registration to autonomously diagnose, treat and discharge patients, Flok Health has established a new precedent for digital clinical practice in a single-payer healthcare system.
Nelson Advisors
Jun 3


Nelson Advisors: 2025 Year in Review
In an investment banking landscape often dominated by career financiers and generalist institutions, Nelson Advisors has cultivated a distinct identity rooted in the operational experience of its leadership. The firm’s "Founders for Founders" philosophy is not merely a marketing tagline but a fundamental operational differentiator that dictates its approach to client selection, deal structuring and negotiation strategy.
Nelson Advisors
Dec 16, 2025


HeartFlow's IPO: Analysis of Market Debut and AI Driven Cardiac Technology Market
The recent initial public offering (IPO) of HeartFlow represents a significant milestone in the convergence of artificial intelligence (AI) and medical technology. The company, which is focused on diagnosing and managing coronary artery disease (CAD), successfully navigated a challenging market to complete a landmark public debut on the Nasdaq Global Select Market under the ticker symbol HTFL. The offering was met with robust investor demand, leading to a significant increase
Nelson Advisors
Aug 9, 2025
bottom of page